0001104659-22-040391.txt : 20220330
0001104659-22-040391.hdr.sgml : 20220330
20220330212654
ACCESSION NUMBER: 0001104659-22-040391
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210913
FILED AS OF DATE: 20220330
DATE AS OF CHANGE: 20220330
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CONTE LISA A
CENTRAL INDEX KEY: 0001008377
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36714
FILM NUMBER: 22788804
MAIL ADDRESS:
STREET 1: 213 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jaguar Health, Inc.
CENTRAL INDEX KEY: 0001585608
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 PINE STREET SUITE 400
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 415-371-8300
MAIL ADDRESS:
STREET 1: 200 PINE STREET SUITE 400
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
FORMER COMPANY:
FORMER CONFORMED NAME: Jaguar Animal Health, Inc.
DATE OF NAME CHANGE: 20130830
4
1
tm2210715-10_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-09-13
0
0001585608
Jaguar Health, Inc.
JAGX
0001008377
CONTE LISA A
C/O JAGUAR HEALTH, INC.
200 PINE STREET, SUITE 400
SAN FRANCISCO
CA
94104
1
1
0
0
CEO and President
Common Stock
2021-09-13
4
P
0
7968
2.51
A
8003
D
Restricted stock units
2022-03-28
4
A
0
606280
0
A
Common Stock
606280
606280
D
Restricted stock units
2022-03-28
4
A
0
25000
0
A
Common Stock
25000
25000
D
On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.
Granted pursuant to the issuer's 2014 Stock Incentive Plan.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022.
The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.
The restricted stock units vest upon (i) successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and (ii) successful completion of the investigator-initiated trials in support of the proof-of-concept requirement for early access program for patient access in Europe.
/s/ Steven R. King, Attorney-in-Fact
2022-03-30